semaglutide diabetes study united states Semaglutide: Review and Place in Therapy for Adults With Type 2 How Long Has Semaglutide Been

Understanding your genetic predispositions in GLP-1 and metabolic pathways may provide context for which administration route aligns best with your physiology

Standard dosing Daily dose: 300-600mcg per day Injection frequency: Once daily, preferably in the morning on an empty stomach Administration route: Subcutaneous injection Most users start at 300mcg to assess tolerance, then increase to 500-600mcg if the lower dose is well-tolerated but results are modest

Supporting vitamin and mineral levels, reducing stress, and starting scalp-supportive treatments early may also help minimize shedding

Clinicians should consider prioritising review for people with type 2 diabetes on the affected GLP-1 RA preparation where: HbA1c greater than 86mmol/mol in the previous 3 to 6 months HbA1c greater than 86mmol/mol prior to starting the GLP1-RA HbA1c not recorded in the previous 6 months Urine albumin creatinine ratio (uACR) greater than 30mg/mmol Self-monitoring glucose readings (or Continuous Glucose Monitoring, where available) are persistently above individualised target range

The chart below from Weight regain and cardiometabolic effects after withdrawal of semaglutide also show a rapid regain after stopping the drugs